Prosecution Insights
Last updated: April 19, 2026

Examiner: SOROUSH, ALI

Tech Center 1600 • Art Units: 1600 1611 1614 1616 1617

This examiner grants 48% of resolved cases

Performance Statistics

47.6%
Allow Rate
-12.4% vs TC avg
785
Total Applications
+29.6%
Interview Lift
1388
Avg Prosecution Days
Based on 776 resolved cases, 2023–2026

Rejection Statute Breakdown

1.7%
§101 Eligibility
21.2%
§102 Novelty
52.1%
§103 Obviousness
16.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18023594 COMPOSITIONS AND METHODS FOR TREATING AMYLOID-RELATED CONDITIONS Final Rejection The Regents of the University of California
17773974 CARDIOPROTECTIVE MICROBUBBLE-LIPOSOMAL DRUG COMPLEXES Final Rejection UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
17927575 COMPOSITIONS AND METHODS FOR SENSITIZING ACUTE MYELOID LEUKEMIAS TO CHEMOTHERAPY Final Rejection Duke University
18273708 Materials and Methods for Treating Viral and Other Medical Conditions Non-Final OA Biotronik AG
18013174 THERAPEUTIC AGENT FOR DRUG-INDUCED BRADYCARDIA AND BRADYARRHYTHMIA Non-Final OA NISSAN CHEMICAL CORPORATION
18037712 SAFFRON AS ANTI-INFLAMMATORY AGENT IN TREATING INFLAMMATORY BOWEL DISEASE Final Rejection HOWARD UNIVERSITY
18245055 USE OF ESTER GROUP-CONTAINING AROMATIC PROPIONAMIDE COMPOUND IN PREPARATION OF MEDICINE FOR TREATING DRY EYE SYNDROME Final Rejection CHANGCHUN GENESCIENCE PHARMACEUTICAL CO., LTD.
17925934 AGENT FOR PROTECTING AND/OR REGENERATING NEUROMUSCULAR JUNCTION Final Rejection ONO PHARMACEUTICAL CO., LTD.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month